Supreme Court Rules Drug Sales Representatives Do Not Qualify For Overtime Pay

Here in the United States we have labor laws that entitle worker’s to compensation for their labor.  Those same laws also protect companies from unlawful lawsuits, etc.  But, what happens when an employee believes they are being treated unfairly, yet the employer doesn’t agree?  The majority of the time a pending lawsuit ensues.

And, that is exactly what happened recently, when 2 salesmen sued their company for what they thought was uncompensated overtime.

But did you know that some industries are not required to pay overtime?  According to the Fair Labor Standards Act many sales jobs are exempt from overtime pay, because they are outside salesmen.  And these men were pharmaceutical sales representatives that worked for drug maker GlaxoSmithKline. 

The two salesmen filed a class-action lawsuit claiming that they were not paid for the 10 to 20 hours they worked each week on average outside the normal business day. Their jobs required them to meet with doctors in their offices, but also to attend conventions, dinners, even golf outings, therefore they believed they were entitled to compensation.  But, the Supreme Court disagreed.

“Outside salesmen” aren’t entitled to overtime pay under the Fair Labor Standards Act. That category now includes drug company sales reps, a divided U.S. Supreme Court has ruled.

The High Court’s 5-4 decision means GlaxoSmithKline will not have to pay overtime to sales representatives who visit doctor’s offices to make pitches for their company’s drugs, The Washington Post reports.

Key to the ruling was whether drug company representatives should be considered “salesmen” — a question that divided the Justices.

In a dissent, the Court’s liberal Justices argued that Glaxo’s “sales reps” shouldn’t fall under the Fair Labor Standards Act’s overtime exemption because they don’t actually make sales. Rather, their jobs require them only to convince doctors to prescribe their company’s drugs, according to The Post.

In dissent, Justice Stephen Breyer said the sales reps do not consummate sales and so should be allowed to claim overtime. Breyer referred to the employees not as salesmen, but as “detailers,” as they are known in the industry. “The detailer’s work, in my view, is more naturally characterized as involving `promotional activities designed to stimulate sales…made by someone else,’” Breyer said, quoting from federal regulations.

“Where in this process does the [employee] sell the product?” Justice Stephen Breyer wrote in the dissent.

Justices Ruth Bader Ginsburg, Elena Kagan and Sonia Sotomayor signed Breyer’s dissent.

Justice Samuel Alito, writing for the majority, said that the drug sales reps’ “end goal was not merely to make physicians aware of the medically appropriate uses of a particular drug. Rather, it was to convince physicians actually to prescribe the drug in appropriate cases.”

And the majority opinion by Justice Samuel Alito found Glaxo’s representatives “bear all the external indicia of salesmen”: They were hired for their sales know-how and worked away from the office with minimal supervision, Alito wrote.

Chief Justice John Roberts and Justices Anthony Kennedy, Antonin Scalia and Clarence Thomas joined with Alito.

Glaxo’s sales reps also collected bonuses based on the company’s drug sales in their regions, The Post reports. Those bonuses played a role in the majority’s decision.

The FLSA’s “outside salesman” overtime exemption “is premised on the belief that exempt employees ‘typically earned salaries well above the minimum wage’ and enjoyed other benefits that  set them apart from the nonexempt workers entitled to overtime pay,’” Alito wrote, citing the law.

About 90,000 drug-company sales representatives are directly affected by the Court’s ruling and are no longer entitled to overtime.



No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Medical Mattresses Pose Risk Of Infection And Contamination

The FDA warns that medical mattresses may not be as clean as once perceived. Routine checks on mattresses are advised as any rips, tears, or excessive wear alter the efficacy. The medical mattresses as well as the covers have an expected life depending on the manufacturer, which should not go unnoticed.

On Third Of Children Medications Are Only Tested On Adults Leading To Improper Use

One third of children medications are not tested on children, but rather adults. Thus, these drugs are approved for adult use. Companies base the dosages off the adult studies, increasing the risk for improper use.

Epilepsy Drug During Pregnancy Linked To Autism

Expectant mothers who take the popular anti-epileptic drug valproate during pregnancy should be aware that there is an increased risk for their child developing autism compared with children of women who did not take the epilepsy drug, according to a recently published Danish study. Valproate is a drug used for the treatment of epilepsy and other [...]

Cough Syrup Responsible For Over 36 Deaths

Pakistani authorities are investigating allegations that cough syrup has killed at least three dozen people, a government official has announced, making this the second time in recent months that medicine is suspected of causing multiple deaths. The deaths from the cough syrup occurred in the eastern city of Gujranwala and nearby villages, said local official [...]

Merck Settles Vioxx Class-Action Lawsuit

In almost a decade old battle, Merck & Co. Inc. has agreed to settle a class action lawsuit filed on behalf of Missouri consumers over its prescription pain reliever Vioxx in a deal that could cost the drugmaker up to $220 million, lawyers for the consumers said. According to CNBC, the agreement announced on November [...]

Latest Medical Device Injury News

Metal-on-Metal Hip Implants Cause Soft Tissue Damage Says FDA

Hip joint deterioration can lead to pain, stiffness or difficulty walking. When these symptoms do not respond to conservative treatment, such as physical therapy, patients may be advised to undergo total hip replacement or hip resurfacing. As part of this treatment, they may receive a “metal-on-metal” hip implant in which the “ball and socket” of [...]

Ethicon Recalls Surgical Stapler

The FDA has announced a voluntary global recall of more than 157,000 Ethicon surgical staplers, due to problems with incomplete firing strokes that may cause faulty staple formation, potentially resulting in painful and severe internal complications for the patient. An Ethicon surgical stapler recall was first announced in August, after reports surfaced where surgeons experienced [...]

Another Device Maker Investigated By DOJ

Earlier this month, cardiovascular device maker Abiomed announced that the US Attorney’s Office was investigating the company’s marketing and labeling of the Impella 2.5 circulatory support device. According to Forbes, the announcement confirmed rumors that had been circulating for at least two weeks, though in the press release the company said it had just been [...]

A Medical Device Horror Story

CNNMoney describes the chilling details of the bone cement horror stories surrounding the medical device company Synthes. In 2009 the U.S. attorney in Philadelphia accused the medical device manufacturer of running illegal clinical trials — essentially, experimenting on humans. Between 2002 and 2004, Synthes tested a product called Norian XR, a cement that has a [...]

Non-FDA Approved Stryker Surgical Device Recall And Alert

Stryker Neptune Waste Management System is the subject of a recent FDA recall and safety alert.  The non-FDA approved device can cause bleeding as well as soft tissue, muscle and vital organ damage. The Stryker Neptune Waste Management System is used during surgical procedures to collect fluid waste from the patient. The Neptune 2 Ultra [...]